Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Orilissa elagolix CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Keytruda Pembrolizumab CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Lynparza Olaparib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Revolade eltrombopag CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Symdeko tezacaftor/ivacaftor CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Tecentriq Atezolizumab Withdrawn
TBD Entrectinib Withdrawn
Latuda lurasidone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Atriance Nelarabine Cancelled
Xospata Gilteritinib Reimburse with clinical criteria and/or conditions Complete
TBD Cabozantinib Withdrawn
Admelog Insulin lispro Cancelled
Erbitux Cetuximab Cancelled
TBD Bevacizumab Cancelled
TBD Rituximab Cancelled
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
Ogivri Trastuzumab Withdrawn
Zytiga Abiraterone Withdrawn
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Beleodaq Belinostat Withdrawn
Blincyto Blinatumomab Withdrawn
Xeljanz tofacitinib Cancelled